Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591

Journal of Nuclear Medicine

Volumn 55, Issue 2, 2014, Pages 294-300

  Tolmachev, Vladimir ^a   Varasteh, Zohreh ^b   Honarvar, Hadis ^a   Hosseinimehr, Seyed Jalal ^a,c   Eriksson, Olof ^b   Jonasson, Per ^d   Frejd, Fredrik Y ^a,d   Abrahmsen, Lars ^e   Orlova, Anna ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Affibody AB   (Sweden)

^e Algeta AS   (Norway)

Author keywords

Affibody molecule; Molecular imaging; PDGFR ; U 87 MG xenograft

Indexed keywords

DOTA Z09591 IN 111; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; 111IN DOTA Z09591; 111IN-DOTA-Z09591; COORDINATION COMPOUND; HYBRID PROTEIN; INDIUM; INDIUM 111; SINGLE HETEROCYCLIC RINGS; TETRAXETAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DISEASE MARKER; DISSOCIATION CONSTANT; DOSIMETRY; FEASIBILITY STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; AFFIBODY MOLECULE; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; MULTIMODAL IMAGING; PDGFRΒ; POSITRON EMISSION TOMOGRAPHY; PROTEIN TERTIARY STRUCTURE; SCINTISCANNING; TUMOR CELL LINE; U-87 MG XENOGRAFT;

111IN; AFFIBODY MOLECULE; MOLECULAR IMAGING; PDGFRΒ; U-87 MG XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COORDINATION COMPLEXES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, INBRED BALB C; MULTIMODAL IMAGING; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897943445     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.121814     Document Type: Article

References (40)

1. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev. 2004;15: 197-204.
2. Tallquist M, Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004;15: 205-213.
3. Hellström M, Kalén M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-βeta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development. 1999; 126: 3047-3055.
4. Östman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res. 2007;97: 247-274.
5. Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell. 2003;3: 439-443.
6. Paulsson J, Sjöblom T, Micke P, et al. Prognostic significance of stromal plateletderived growth factor beta-receptor expression in human breast cancer. Am J Pathol. 2009;175: 334-341.
7. Hägglöf C, Hammarsten P, Josefsson A. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS ONE. 2010;5: e10747.
8. Yonemori K, Tsuta K, Ando M, et al. Contrasting prognostic implications of platelet-derived growth factor receptor-b and vascular endothelial growth factor receptor-2 in patients with angiosarcoma. Ann Surg Oncol. 2011;18: 2841-2850.
9. Patel SH, Kneuertz PJ, Delgado M, et al. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. Ann Surg Oncol. 2011;18: 3384-3390.
10. Donnem T, Andersen S, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Prognostic impact of angiogenic markers in non-small-cell lung cancer is related to tumor size. Clin Lung Cancer. 2011;12: 106-115.
11. Laimer D, Dolznig H, Kollmann K, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012;18: 1699-1704.
12. Ruan J, Luo M, Wang C, et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013;121: 5192-5202.
13. Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ. Targeting PDGFR-β in cholangiocarcinoma. Liver Int. 2012;32: 400-409.
14. Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui I. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Sci. 2011;102: 1949-1957.
15. 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med. 2012;53: 567-574.
16. van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012; 33: 607-615.
17. Slobbe P, Poot AJ, Windhorst AD, van Dongen GA. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. Drug Discov Today. 2012;17: 1175-1187.
18. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor-Tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 2010;11: 992-1000.
19. Altai M, Tolmachev V, Orlova A. Radiolabelled probes targeting tyrosine-kinase receptors for personalized medicine. Curr Pharm Des. September 11, 2013 [Epub ahead of print].
20. 11C]Sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/BCRP knockout mice. Bioorg Med Chem Lett. 2011;21: 2220-2223.
21. 18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Bioorg Med Chem Lett. 2005;15: 4380-4384.
22. Kil KE, Ding YS, Lin KS, et al. Synthesis and positron emission tomography studies of carbon-11-labeled Imatinib (Gleevec). Nucl Med Biol. 2007;34: 153-163.
23. Gelovani JG. Molecular imaging of epidermal growth factor receptor expressionactivity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev. 2008;27: 645-653.
24. Ahlgren S, Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol. 2010;11: 581-589.
25. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14: 2999-3019.
26. 68Ga-labeled Affibody molecules. J Nucl Med. 2010;51: 892-897.
27. 111In]ABY-025 metastatic detection capability in females with metastatic breast cancer [abstract]. J Nucl Med. 2012;53(suppl 1): 220.
28. Lindborg M, Cortez E, Hoiden-Guthenberg I, et al. Engineered high-Affinity Affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J Mol Biol. 2011;407: 298-315.
29. Feldwisch J, Tolmachev V. Engineering of Affibody molecules for therapy and diagnostics. Methods Mol Biol. 2012;899: 103-126.
30. Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem. 2008;19: 235-243.
31. 111In-DOTA-ZHER2: 342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23: 435-442.
32. Björke H, Andersson K. Automated, high-resolution cellular retention and uptake studies in vitro. Appl Radiat Isot. 2006;64: 901-905.
33. Rajkumar VS, Boxer G, Robson M, Muddle J, Papastavrou Y, Pedley RB. A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma. Tumour Biol. 2012;33: 2019-2029.
34. Askoxylakis V, Marr A, Altmann A, et al. Peptide-based targeting of the plateletderived growth factor receptor beta. Mol Imaging Biol. 2013;15: 212-221.
35. Pahara J, Shi H, Chen X, Wang Z. Dimerization drives PDGF receptor endocytosis through a C-Terminal hydrophobic motif shared by EGF receptor. Exp Cell Res. 2010;316: 2237-2250.
36. Tolmachev V, Tran TA, Rosik D, Abrahmsén L, Sjöberg A, Orlova A. Tumor targeting using Affibody molecules: interplay of affinity, target expression level and binding site composition. J Nucl Med. 2012;53: 953-960.
37. 18F]FBEM-Z(HER2: 342)-Affibody molecule-A new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging. 2008;35: 1008-1018.
38. 99mTc-labeled recombinant Affibody molecules improves their biodistribution and imaging properties. J Nucl Med. 2011;52: 461-469.
39. 111In-DOTA-Z EGFR: 2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging. 2010;37: 613-622.
40. Tolmachev V, Wallberg H, Sandström M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging. 2011;38: 531-539.